Salma Younas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Salma Younas has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Fahmida Shaik
Medical Education, Gandhi Medical College, Secunderabad, IND
2 shared publicationsSwati Thareja
Internal Medicine, The Hans Foundation, Delhi, IND
2 shared publicationsSweta Sahu
Internal Medicine, J.J.M. Medical College, Davanagere, IND
2 shared publications- Sweta Sahu
JJM Medical College, Davanagere, India
2 shared publications Akshita Bhalla
Internal Medicine, Punjab Institute of Medical Sciences, Jalandhar, IND
1 shared publicationAnushka Shahi
Internal Medicine, Sri Aurobindo Institute of Medical Sciences, Indore, IND
1 shared publication
Latest Publications
- Open Access
- 28 October 2025
- Published by MDPI AG in Journal of Vascular Diseases
- Vol. 4 (4) , 42
Salt Substitutes in Low-Income Settings: Blood Pressure Benefits, Cardiovascular Outcomes, and Safety Considerations: A Narrative Review
Background: Hypertension remains a leading cause of cardiovascular morbidity and mortality, disproportionately affecting low- and middle-income countries (LMICs), where healthcare access and awareness are limited. Excessive sodium intake, often from discretionary salt used in cooking, contributes significantly to this burden. Salt substitutes, typically formulated by partially replacing sodium chloride with potassium chloride or other minerals, offer a cost-effective dietary intervention to lower blood pressure (BP) and reduce cardiovascular risk, particularly in resource-constrained settings. Objective: This review examines the efficacy of low-sodium salt substitutes (LSSS) in reducing blood pressure (BP) and its effects on cardiovascular (CV) outcomes, safety concerns, and challenges to their implementation in LMICs. Methods: We conducted a comprehensive narrative review of studies published between 1994 and 2024 using PubMed, Embase, and Scopus databases. Eligible studies included randomized controlled trials, systematic reviews, observational studies, and implementation research that evaluated the effects of LSSS on BP, CV outcomes, safety, and feasibility in LMIC contexts. Thematic synthesis was used to summarize the findings. Key Findings: Salt substitutes consistently lowered systolic and diastolic BP across diverse populations, with mean reductions ranging from 3 to 5 mmHg. Trials have also demonstrated reductions in stroke incidence, CV events, and all-cause mortality. However, the benefits were mostly derived from studies conducted in China and other upper-middle-income settings. Safety concerns (particularly hyperkalemia in individuals with chronic kidney disease or RAAS inhibitors) warrant targeted risk screening and public education. Implementation barriers in LMICs include cost, limited availability, poor awareness, and a lack of regulatory oversight. Conclusions: Salt substitutes present a promising, scalable strategy to reduce BP and CV disease burden in LMICs. However, their adoption must be context-specific, culturally sensitive, and supported by government subsidies, regulatory frameworks, and educational campaigns. Future trials should evaluate the long-term safety and cost-effectiveness in underrepresented LMIC populations to guide equitable public health interventions.
- 28 October 2025
- Published by MDPI AG in Journal of Vascular Diseases
- Vol. 4 (4) , 42
Open AccessSalt Substitutes in Low-Income Settings: Blood Pressure Benefits, Cardiovascular Outcomes, and Safety Considerations: A Narrative Review
Background: Hypertension remains a leading cause of cardiovascular morbidity and mortality, disproportionately affecting low- and middle-income countries (LMICs), where healthcare access and awareness are limited. Excessive sodium intake, often from discretionary salt used in cooking, contributes significantly to this burden. Salt substitutes, typically formulated by partially replacing sodium chloride with potassium chloride or other minerals, offer a cost-effective dietary intervention to lower blood pressure (BP) and reduce cardiovascular risk, particularly in resource-constrained settings. Objective: This review examines the efficacy of low-sodium salt substitutes (LSSS) in reducing blood pressure (BP) and its effects on cardiovascular (CV) outcomes, safety concerns, and challenges to their implementation in LMICs. Methods: We conducted a comprehensive narrative review of studies published between 1994 and 2024 using PubMed, Embase, and Scopus databases. Eligible studies included randomized controlled trials, systematic reviews, observational studies, and implementation research that evaluated the effects of LSSS on BP, CV outcomes, safety, and feasibility in LMIC contexts. Thematic synthesis was used to summarize the findings. Key Findings: Salt substitutes consistently lowered systolic and diastolic BP across diverse populations, with mean reductions ranging from 3 to 5 mmHg. Trials have also demonstrated reductions in stroke incidence, CV events, and all-cause mortality. However, the benefits were mostly derived from studies conducted in China and other upper-middle-income settings. Safety concerns (particularly hyperkalemia in individuals with chronic kidney disease or RAAS inhibitors) warrant targeted risk screening and public education. Implementation barriers in LMICs include cost, limited availability, poor awareness, and a lack of regulatory oversight. Conclusions: Salt substitutes present a promising, scalable strategy to reduce BP and CV disease burden in LMICs. However, their adoption must be context-specific, culturally sensitive, and supported by government subsidies, regulatory frameworks, and educational campaigns. Future trials should evaluate the long-term safety and cost-effectiveness in underrepresented LMIC populations to guide equitable public health interventions.
- Top Cited PapersOpen Access
- 30 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e81447
Gut Microbiota and Mental Health: A Comprehensive Review of Gut-Brain Interactions in Mood Disorders
The human gut flora of trillions of bacteria is vital for general health and greatly influences digestion, immune system function, and brain development. Through neuronal, hormonal, and immunological channels, the gut-brain axis (GBA), a bidirectional communication network, links the gut microbiota to the central nervous system (CNS). This relationship has been linked to affective diseases, including depression and anxiety, as well as mental health issues. This review explores the intricate relationship between gut bacteria and mood disorders, focusing on how gut microbiota-host interactions, immune system modulation, and neurotransmitter control support mental health. The function of important microbial metabolites, including short-chain fatty acids (SCFAs), in preserving blood-brain barrier integrity and modulating neuroinflammation is covered in this review. It also examines the bidirectional impact between gut health and mental health, including how dysbiosis could aggravate mood disorders and how depressed states might change the composition of gut bacteria. Furthermore, we discuss how psychotropic drugs affect gut flora and consider other elements such as nutrition and lifestyle that affect gut microbiome composition. Potential paths for treating mood disorders through gut microbiota modification are presented as emerging treatment techniques, including probiotics, nutritional therapies, and precision medicine. The development of new therapeutic approaches for mood disorders depends on the awareness of the GBA. Gut bacteria significantly affect mental health through immune modulation, neurotransmitter generation, and other intricate processes. Future studies should concentrate on large, varied populations to better understand these interactions and to create customized treatments that combine gut microbiota modulation with conventional mental health therapies.
- 30 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e81447
Top Cited PapersOpen AccessGut Microbiota and Mental Health: A Comprehensive Review of Gut-Brain Interactions in Mood Disorders
The human gut flora of trillions of bacteria is vital for general health and greatly influences digestion, immune system function, and brain development. Through neuronal, hormonal, and immunological channels, the gut-brain axis (GBA), a bidirectional communication network, links the gut microbiota to the central nervous system (CNS). This relationship has been linked to affective diseases, including depression and anxiety, as well as mental health issues. This review explores the intricate relationship between gut bacteria and mood disorders, focusing on how gut microbiota-host interactions, immune system modulation, and neurotransmitter control support mental health. The function of important microbial metabolites, including short-chain fatty acids (SCFAs), in preserving blood-brain barrier integrity and modulating neuroinflammation is covered in this review. It also examines the bidirectional impact between gut health and mental health, including how dysbiosis could aggravate mood disorders and how depressed states might change the composition of gut bacteria. Furthermore, we discuss how psychotropic drugs affect gut flora and consider other elements such as nutrition and lifestyle that affect gut microbiome composition. Potential paths for treating mood disorders through gut microbiota modification are presented as emerging treatment techniques, including probiotics, nutritional therapies, and precision medicine. The development of new therapeutic approaches for mood disorders depends on the awareness of the GBA. Gut bacteria significantly affect mental health through immune modulation, neurotransmitter generation, and other intricate processes. Future studies should concentrate on large, varied populations to better understand these interactions and to create customized treatments that combine gut microbiota modulation with conventional mental health therapies.
- Open Access
- 3 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e78462
Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies
Pediatric inflammatory bowel disease (PIBD), including Crohn’s disease and ulcerative colitis, has emerged as a significant global health challenge with rising incidence rates. Unlike adult inflammatory bowel disease, PIBD presents complexities, including growth impairment, nutritional deficiencies, and psychosocial challenges that necessitate tailored management strategies. This article reviews current diagnostic and emerging treatment strategies to highlight the evolution from traditional therapies such as aminosalicylates, corticosteroids, and immunomodulators to advanced biologic agents like infliximab and adalimumab. Emerging biological therapies, including vedolizumab and ustekinumab, show promise, while novel small molecule therapies such as Janus kinase (JAK) inhibitors are under investigation for potential use in the pediatric population. Supportive treatments, including exclusive enteral nutrition, modified diets, and probiotics, play a critical role in comprehensive disease management. Stem cell therapy and fecal microbiota transplant represent innovative approaches still under clinical evaluation. The review underscores the significance of holistic care, incorporating mind-body interventions and psychosocial support to improve patient quality of life. Key challenges persist, such as infection risks associated with long-term biological therapy use, gaps in pediatric-specific guidelines, and the limited inclusion of children in clinical trials. Future recommendations emphasize the importance of structured transition programs bridging pediatric and adult care, regular updates to clinical guidelines, and the integration of precision medicine to personalize treatment plans. Continued research and collaboration are essential for advancing the understanding and management of PIBD, ensuring that pediatric patients benefit from the most effective, evidence-based care available.
- 3 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e78462
Open AccessInflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies
Pediatric inflammatory bowel disease (PIBD), including Crohn’s disease and ulcerative colitis, has emerged as a significant global health challenge with rising incidence rates. Unlike adult inflammatory bowel disease, PIBD presents complexities, including growth impairment, nutritional deficiencies, and psychosocial challenges that necessitate tailored management strategies. This article reviews current diagnostic and emerging treatment strategies to highlight the evolution from traditional therapies such as aminosalicylates, corticosteroids, and immunomodulators to advanced biologic agents like infliximab and adalimumab. Emerging biological therapies, including vedolizumab and ustekinumab, show promise, while novel small molecule therapies such as Janus kinase (JAK) inhibitors are under investigation for potential use in the pediatric population. Supportive treatments, including exclusive enteral nutrition, modified diets, and probiotics, play a critical role in comprehensive disease management. Stem cell therapy and fecal microbiota transplant represent innovative approaches still under clinical evaluation. The review underscores the significance of holistic care, incorporating mind-body interventions and psychosocial support to improve patient quality of life. Key challenges persist, such as infection risks associated with long-term biological therapy use, gaps in pediatric-specific guidelines, and the limited inclusion of children in clinical trials. Future recommendations emphasize the importance of structured transition programs bridging pediatric and adult care, regular updates to clinical guidelines, and the integration of precision medicine to personalize treatment plans. Continued research and collaboration are essential for advancing the understanding and management of PIBD, ensuring that pediatric patients benefit from the most effective, evidence-based care available.
- Open Access
- 3 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e78421
Efficacy of Non-invasive Biomarkers in Diagnosing Non-alcoholic Fatty Liver Disease (NAFLD) and Predicting Disease Progression: A Systematic Review
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with significant global prevalence and a strong association with metabolic syndrome, obesity, and diabetes. Early diagnosis and prediction of disease progression are critical for effective management. Non-invasive biomarkers have emerged as promising alternatives to liver biopsy, offering safer and more accessible diagnostic and prognostic options. This systematic review evaluates the efficacy of non-invasive biomarkers in diagnosing NAFLD and predicting disease progression, focusing on diagnostic accuracy, clinical utility, and limitations. A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including studies published between 2010 and 2024. Databases such as PubMed, Embase, and Scopus were searched using relevant keywords and Boolean operators. Inclusion criteria comprised studies evaluating adults (18+) with NAFLD using non-invasive biomarkers, compared to liver biopsy or other standards, and reporting diagnostic metrics such as sensitivity, specificity, and area under the curve (AUC). Data were extracted systematically, and study quality was assessed using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) and the Newcastle-Ottawa Scale. The nine studies include a range of biomarkers such as serum markers (Pro-C3, NIS4), imaging techniques (MRI-PDFF, cT1), and composite scores (cTAG, NFS). Diagnostic accuracy was high, with area under the curve (AUC) values ranging from 0.81 to 0.90 for detecting significant fibrosis and at-risk non-alcoholic steatohepatitis (NASH). Imaging tools such as MRI-PDFF offered superior reproducibility and whole-liver assessments, while composite biomarkers such as NIS4 demonstrated robust sensitivity but moderate specificity. Notable heterogeneity in populations and methodologies was observed. Non-invasive biomarkers show comparable diagnostic performance to liver biopsy while offering significant advantages in safety, scalability, and patient adherence. However, gaps remain, including the need for validation in diverse populations and improved specificity for advanced fibrosis. Integrating non-invasive biomarkers into clinical practice could revolutionize NAFLD management by enabling early diagnosis, guiding treatment, and reducing reliance on invasive methods. Future research should focus on validating these tools across diverse cohorts and developing novel biomarkers to address existing limitations.
- 3 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e78421
Open AccessEfficacy of Non-invasive Biomarkers in Diagnosing Non-alcoholic Fatty Liver Disease (NAFLD) and Predicting Disease Progression: A Systematic Review
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with significant global prevalence and a strong association with metabolic syndrome, obesity, and diabetes. Early diagnosis and prediction of disease progression are critical for effective management. Non-invasive biomarkers have emerged as promising alternatives to liver biopsy, offering safer and more accessible diagnostic and prognostic options. This systematic review evaluates the efficacy of non-invasive biomarkers in diagnosing NAFLD and predicting disease progression, focusing on diagnostic accuracy, clinical utility, and limitations. A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including studies published between 2010 and 2024. Databases such as PubMed, Embase, and Scopus were searched using relevant keywords and Boolean operators. Inclusion criteria comprised studies evaluating adults (18+) with NAFLD using non-invasive biomarkers, compared to liver biopsy or other standards, and reporting diagnostic metrics such as sensitivity, specificity, and area under the curve (AUC). Data were extracted systematically, and study quality was assessed using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) and the Newcastle-Ottawa Scale. The nine studies include a range of biomarkers such as serum markers (Pro-C3, NIS4), imaging techniques (MRI-PDFF, cT1), and composite scores (cTAG, NFS). Diagnostic accuracy was high, with area under the curve (AUC) values ranging from 0.81 to 0.90 for detecting significant fibrosis and at-risk non-alcoholic steatohepatitis (NASH). Imaging tools such as MRI-PDFF offered superior reproducibility and whole-liver assessments, while composite biomarkers such as NIS4 demonstrated robust sensitivity but moderate specificity. Notable heterogeneity in populations and methodologies was observed. Non-invasive biomarkers show comparable diagnostic performance to liver biopsy while offering significant advantages in safety, scalability, and patient adherence. However, gaps remain, including the need for validation in diverse populations and improved specificity for advanced fibrosis. Integrating non-invasive biomarkers into clinical practice could revolutionize NAFLD management by enabling early diagnosis, guiding treatment, and reducing reliance on invasive methods. Future research should focus on validating these tools across diverse cohorts and developing novel biomarkers to address existing limitations.
- Open Access
- 9 December 2024
- Published by Springer Nature in Cureus
- Vol. 16 (12) , e75434
Siblings With Berardinelli-Seip Congenital Lipodystrophy: Clinical Insights and Challenges
Berardinelli-Seip congenital lipodystrophy (BSCL), also known as congenital generalized lipodystrophy (CGL), is an exceptionally rare autosomal recessive disorder marked by a significant deficiency of adipose tissue throughout the body. This lack of adipose tissue, normally found beneath the skin and between internal organs, leads to impaired adipocyte formation and fat storage, causing lipids to accumulate in atypical tissues such as muscles and the liver. The extent of adipose tissue loss directly influences the severity of symptoms, which can include a muscular appearance, increased appetite, bone cysts, marrow fat depletion, acromegalic features, severe insulin resistance, skeletal muscle hypertrophy, hypertrophic cardiomyopathy, hepatic steatosis, hepatomegaly, cirrhosis, and intellectual disability. We present a case series of two siblings with BSCL: a nine-year-old boy and his seven-year-old sister, each with unique manifestations of the disorder. The older sibling presented with high-grade fever and right ankle pain, possibly indicative of a calcified deposit, alongside complications such as hyperglycemia (managed without insulin) and moderate pulmonary arterial hypertension (PAH) with tricuspid regurgitation (TR). The younger sibling displayed similar metabolic and cardiovascular complications, including hepatomegaly and early signs of cardiac involvement. Both cases required comprehensive evaluations, revealing anemia, thrombocytopenia, elevated leukocyte count, and high C-reactive protein (CRP) levels. The children were managed with high-potency antibiotics, leading to a marked improvement in their overall conditions. These cases demonstrate the broad spectrum of clinical manifestations associated with BSCL and highlight the importance of a multidisciplinary approach for effective management. Although limited by the small sample size, this case series shows the importance of a multidisciplinary approach in addressing the complex and overlapping symptoms of BSCL, which often mimic more common conditions. Increased awareness among healthcare providers is crucial for ensuring timely diagnosis and appropriate intervention, particularly in pediatric patients.
- 9 December 2024
- Published by Springer Nature in Cureus
- Vol. 16 (12) , e75434
Open AccessSiblings With Berardinelli-Seip Congenital Lipodystrophy: Clinical Insights and Challenges
Berardinelli-Seip congenital lipodystrophy (BSCL), also known as congenital generalized lipodystrophy (CGL), is an exceptionally rare autosomal recessive disorder marked by a significant deficiency of adipose tissue throughout the body. This lack of adipose tissue, normally found beneath the skin and between internal organs, leads to impaired adipocyte formation and fat storage, causing lipids to accumulate in atypical tissues such as muscles and the liver. The extent of adipose tissue loss directly influences the severity of symptoms, which can include a muscular appearance, increased appetite, bone cysts, marrow fat depletion, acromegalic features, severe insulin resistance, skeletal muscle hypertrophy, hypertrophic cardiomyopathy, hepatic steatosis, hepatomegaly, cirrhosis, and intellectual disability. We present a case series of two siblings with BSCL: a nine-year-old boy and his seven-year-old sister, each with unique manifestations of the disorder. The older sibling presented with high-grade fever and right ankle pain, possibly indicative of a calcified deposit, alongside complications such as hyperglycemia (managed without insulin) and moderate pulmonary arterial hypertension (PAH) with tricuspid regurgitation (TR). The younger sibling displayed similar metabolic and cardiovascular complications, including hepatomegaly and early signs of cardiac involvement. Both cases required comprehensive evaluations, revealing anemia, thrombocytopenia, elevated leukocyte count, and high C-reactive protein (CRP) levels. The children were managed with high-potency antibiotics, leading to a marked improvement in their overall conditions. These cases demonstrate the broad spectrum of clinical manifestations associated with BSCL and highlight the importance of a multidisciplinary approach for effective management. Although limited by the small sample size, this case series shows the importance of a multidisciplinary approach in addressing the complex and overlapping symptoms of BSCL, which often mimic more common conditions. Increased awareness among healthcare providers is crucial for ensuring timely diagnosis and appropriate intervention, particularly in pediatric patients.
- Open Access
- 20 October 2024
- Published by Springer Nature in Cureus
- Vol. 16 (10) , e71940
Impact of Obstructive Sleep Apnea on Cardiovascular Health: A Systematic Review
Obstructive sleep apnea (OSA) is characterized by recurrent interruptions in breathing during sleep and is associated with a wide range of significant health concerns, particularly cardiovascular complications. This review focuses on the two primary forms of sleep apnea, namely, obstructive and central, with OSA being the most prevalent and commonly linked to conditions, such as hypertension, arrhythmias, and heart failure. Intermittent hypoxemia, activation of the sympathetic nervous system, systemic inflammation, and remodeling of the ventricles are some of the pathophysiological mechanisms that link OSA to cardiovascular disease (CVD). These all lead to higher oxidative stress and endothelial dysfunction. These processes elevate the risk of CVDs, including hypertension, coronary artery disease, and stroke. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and examined studies published over the last 15 years. The search strategy utilized key terms such as “sleep disorder,” “apnea,” “hypertension,” “cardiovascular disease (CVD),” and “treatment outcomes” across multiple databases, including PubMed, Scopus, Embase, and the Cochrane Library. A total of 128 unique studies were identified, of which 10 met the inclusion criteria and were included in the final analysis. These studies consistently highlighted the significant role OSA plays in exacerbating cardiovascular risks, particularly in patients with comorbid conditions such as obesity, hypertension, and diabetes.
- 20 October 2024
- Published by Springer Nature in Cureus
- Vol. 16 (10) , e71940
Open AccessImpact of Obstructive Sleep Apnea on Cardiovascular Health: A Systematic Review
Obstructive sleep apnea (OSA) is characterized by recurrent interruptions in breathing during sleep and is associated with a wide range of significant health concerns, particularly cardiovascular complications. This review focuses on the two primary forms of sleep apnea, namely, obstructive and central, with OSA being the most prevalent and commonly linked to conditions, such as hypertension, arrhythmias, and heart failure. Intermittent hypoxemia, activation of the sympathetic nervous system, systemic inflammation, and remodeling of the ventricles are some of the pathophysiological mechanisms that link OSA to cardiovascular disease (CVD). These all lead to higher oxidative stress and endothelial dysfunction. These processes elevate the risk of CVDs, including hypertension, coronary artery disease, and stroke. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and examined studies published over the last 15 years. The search strategy utilized key terms such as “sleep disorder,” “apnea,” “hypertension,” “cardiovascular disease (CVD),” and “treatment outcomes” across multiple databases, including PubMed, Scopus, Embase, and the Cochrane Library. A total of 128 unique studies were identified, of which 10 met the inclusion criteria and were included in the final analysis. These studies consistently highlighted the significant role OSA plays in exacerbating cardiovascular risks, particularly in patients with comorbid conditions such as obesity, hypertension, and diabetes.